Research to establish whether a vaccine can slow down progression of disease in people already infected with HIV has started at the University of Limpopo, Medunsa campus. The randomised controlled trial is looking to recruit 200 volunteers between the ages of 18–45. The Phase II clinical trial, of the vaccine candidate that is called TAT, will investigate the safety of the product and whether it generates an immune response. "This is a protein that is produced by the virus. It's a very important regulatory protein in the development of the disease," said Maphoshane Nchabeleng, the principal investigator.